Stock BCART BIOCARTIS GROUP NV
Add to a list
To use this feature you must be a member
Log inSign up

Biocartis Group NV Stock

Equities

BCART

BE0974281132

Medical Equipment, Supplies & Distribution

Real-time Euronext Bruxelles
Other stock markets
 11:35:06 2023-09-22 am EDT 		5-day change 1st Jan Change
0.29 EUR +1.05% Intraday chart for Biocartis Group NV -.--% -.--%
2023 Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress CI
2023 Biocartis, APIS Assay Technologies to Commercialize Estrogen Receptor-positive Mutations Kit MT

Financials

Sales 2021 54.9M 58.84M Sales 2022 57.98M 62.13M Capitalization 48.52M 52M
Net income 2021 -71M -76.09M Net income 2022 -65M -69.66M EV / Sales 2021 5.62 x
Net Debt 2021 101M 108M Net Debt 2022 96.23M 103M EV / Sales 2022 2.5 x
P/E ratio 2021
-2.91 x
P/E ratio 2022
-0.49 x
Employees 526
Yield 2021 *
-
Yield 2022
-
Free-Float 93.41%
More Fundamentals * Assessed data

Chart Biocartis Group NV

Dynamic Chart

Latest news about Biocartis Group NV

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress CI
Biocartis, APIS Assay Technologies to Commercialize Estrogen Receptor-positive Mutations Kit MT
Biocartis Group NV Announces Expansion of Its Collaboration with APIS Assay Technologies Ltd to Commercialize the APIS ESR1 Mutations Kit CI
Biocartis Winding Down Begins with Creditors' Takeover of Operating Units MT
Biocartis Group NV Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Biocartis Appoints New Medical Advisory Board of Renowned Practice Leaders CI
Biocartis, Eli Lilly to Develop Diagnostics System to Identify Therapy-eligible Lung Cancer Patients MT
Biocartis Group NV Partners with Lilly to Explore Biomarker Testing for NSCLC Patients Using the Idylla? Platform CI
Molecular Diagnostics Company Biocartis Group Names New CFO MT
Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023 CI
Biocartis Group NV Appoints George Cardoza as Head of Service Delivery, Effective 7 August 2023 CI
Biocartis CFO to Depart in August MT
Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO CI
Certain ordinary shares of Biocartis Group NV are subject to a Lock-Up Agreement Ending on 2-JUN-2023. CI
Biocartis, HiloProbe Enter Commercialization Partnership for Colorectal Cancer Test MT
More news

Analyst Recommendations on Biocartis Group NV

Berenberg Diagnostics Conference FA
Biocartis' Lung Cancer Test Shown to Improve Patient Survival Rates in UK Study MT
Exane BNP Paribas Diagnostics Imaging &Life Sciences CEO Conference FA
Berenberg European Opportunities Conference FA
Berenberg Belgian Conference FA
More recommendations

Press releases Biocartis Group NV

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings) GL
Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings) GL
Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings) AQ
Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion GL
Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting GL
More press releases

News in other languages on Biocartis Group NV

Persbericht Biocartis Group NV: Mededeling betreffende uitwinning door gewaarborgde schuldeisers
Biocartis selecteert vier studie abstracts over Idylla voor ESMO-congres
Persbericht Biocartis Group NV: Vier abstracts, die uitstekende resultaten voor Idylla™ tonen, worden gepresenteerd op het European Society of Molecular Oncology (ESMO) congres
Biocartis lanceert een borstkankerportfolio
Persbericht Biocartis Group NV: Biocartis steunt Borstkankermaand met lancering van een borstkankerportfolio
More news

Highs and lows

1 week
0.29
Extreme 0.287
0.29
1 month
0.29
Extreme 0.287
0.29
Current year
0.29
Extreme 0.287
0.29
1 year
0.29
Extreme 0.285
0.64
3 years
0.29
Extreme 0.285
4.78
5 years
0.29
Extreme 0.285
12.44
10 years
0.29
Extreme 0.285
15.00
More quotes

Managers and Directors - Biocartis Group NV

Managers TitleAgeSince
John Roger Moody CEO
 Chief Executive Officer 56 23-04-23
Herman Verrelst CHM
 Chairman 51 17-08-30
George Cardoza DFI
 Director of Finance/CFO 62 23-08-06
Members of the board TitleAgeSince
John Roger Moody CEO
 Chief Executive Officer 56 23-04-23
Christian Reinaudo BRD
 Director/Board Member 70 18-05-10
Luc Gijsens BRD
 Director/Board Member 71 18-05-10
More insiders

Quotes

Date Price Change Volume
24-04-24 0.29 -.--% 0
24-04-23 0.29 -.--% 0
24-04-22 0.29 -.--% 0
24-04-19 0.29 -.--% 0
24-04-18 0.29 -.--% 0

Real-time Euronext Bruxelles, September 22, 2023 at 11:35 am EDT

More quotes

Company Profile

Biocartis Group NV specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes. Net sales by source of income are mainly distributed between products sales (78.3%) and sale of collaboration services (19.3%; especially research and development services).
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-09-04 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Medical Equipment

1st Jan change Capi.
BIOCARTIS GROUP NV Stock Biocartis Group NV
-.--% 29.1M
SHOCKWAVE MEDICAL, INC. Stock Shockwave Medical, Inc.
+72.58% 12.34B
PENUMBRA, INC. Stock Penumbra, Inc.
-18.04% 7.98B
GETINGE AB Stock Getinge AB
+3.57% 5.81B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+6.65% 5.04B
APT MEDICAL INC. Stock APT Medical Inc.
+20.83% 4.31B
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-20.27% 4.03B
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-41.19% 2.21B
SKAN GROUP AG Stock SKAN Group AG
+0.25% 1.99B
SHENZHEN YHLO BIOTECH CO., LTD. Stock Shenzhen YHLO Biotech Co., Ltd.
+4.02% 1.87B
Medical Equipment
  1. Stock Market
  2. Equities
  3. BCART Stock